Dose Escalation

Dose Escalation

Dose escalation is a basic strategy in clinical pharmacology. Patients start on a low dose that is raised in steps at set intervals until the target dose is reached. This gives the body time to adjust to the drug and cuts the number and severity of side effects that a full starting dose might cause. It matters most for drugs that affect the gut, appetite or metabolism, where a sudden full dose can trigger significant side effects.

For incretin-based drugs such as retatrutide, dose escalation is critical, because GLP-1 receptor activation often causes gastrointestinal side effects such as nausea, vomiting and diarrhea. Starting low and increasing slowly, usually every four weeks, makes the drug much easier to tolerate. In the Phase 2 retatrutide trials, participants started on lower doses and worked up to their assigned maintenance dose over several weeks, which helped limit the gastrointestinal side effects linked to the drug’s triple agonist action.

Dose escalation is also central to Phase 1 trials, where single ascending dose and multiple ascending dose designs find the maximum tolerated dose and map the dose-response relationship. What these studies learn directly sets the dose ranges for later Phase 2 and Phase 3 trials, so dose escalation is a foundation of drug development.